Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of rDEN3Δ30
NCT02684383Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Primary completion
- Jul 2016
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in dengue fever comparing rDEN3Δ30 vaccine with Placebo (2 arms). Primary endpoints: Frequency of vaccine-related adverse events at Day 28 and Level of anti-DENV-3 neutralizing antibody at Day 180. Status: completed.
02
Drugs
rDEN3Δ30
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT02684383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02684383.